This document summarizes new targeted therapies for non-small cell lung cancers (NSCLCs). It discusses targeted agents for driver mutations in adenocarcinomas, including crizotinib for ALK rearrangements and ROS1 fusions, selective EGFR inhibitors, and investigational therapies targeting KRAS, BRAF, HER2 and MET alterations. Crizotinib improves outcomes over chemotherapy for ALK-positive NSCLC. Second generation ALK and EGFR inhibitors show responses in patients resistant to first-line therapies. The document also briefly mentions targeted approaches for squamous cell carcinomas but notes driver mutations are less common in this histology.